We performed a comprehensive review of randomized clinical trials (RCTs) evaluating SGLT-2 inhibitors in HF patients with different values of ejection fraction (EF) to create a more lucid concept of these interventions on patients’ survival and quality of life besides the worsening of heart failure. This evidence concerns the gene SLC5A2 and hydrops fetalis.